Amolyt Pharma

We’re happy to report that Amolyt’s previously announced acquisition by AstraZeneca has closed! Read the press release here: https://bit.ly/3Wp2rzL

It's #WorldHypoPARADay, an important day for us at Amolyt! As a team, we are dedicated to supporting the HypoPARA community and advocating for patients living with #hypoparathyroidism (HPT), a rare endocrine disease. We remain committed to advancing our lead candidate in Phase 3 development, which is designed to address the key therapeutic goals of HPT: normal blood calcium levels, normal urinary calcium excretion, and balanced bone turnover. Learn more here: https://bit.ly/3RVQcca

In honor of #WorldHypoPARADay, Asociacion Espanola de Cancer de Tiroides is hosting an event tomorrow, June 1, for patients with #hypoparathyroidism, including experts in the field. Watch a live broadcast of the meeting here: https://lnkd.in/gkdFiCt2

Today, we announced we’re presenting data on our #hypoparathyroidism and #acromegaly programs at the 10th International Congress of the Growth Hormone Research Society from May 10-11 in Stockholm, the 26th European Society of Endocrinology Congress in Stockholm from May 11-14, and the 2024 Endocrine Society Meeting in Boston from June 1-3. Learn more here: https://brnw.ch/21wJxsN #ECE2024 #ENDO2024

Today, we announced our lead candidate in development for #hypoparathyroidism received Fast Track Designation from the FDA. To learn more, read the press release here: https://brnw.ch/21wJoFS

#ICYMI, our CMO, Mark Sumeray MD MS FRCS, recently shared his strategies for advancing clinical development through regulatory interactions at the @The Conference Forum's CMO Summit 360. Learn more about the conference here: https://brnw.ch/21wJav2

If you're attending The Conference Forum's CMO Summit 360, be sure to check out a panel on maximizing regulatory interactions featuring our CMO, Mark Sumeray MD MS FRCS, on April 17 at 4:15 pm ET. Learn more here: https://brnw.ch/21wIGBJ #CMO360

We are proud to share that Amolyt has entered into a definitive agreement to be acquired by AstraZeneca! This strategic transaction marks a significant milestone in our journey to develop innovative treatments for patients with rare endocrine disease. As leaders in rare disease, AstraZeneca is uniquely positioned to drive the late-stage development and global commercialization of eneboparatide for hypoparathyroidism and to advance our early-stage pipeline, bringing new hope to patients worldwide. We are grateful for the support of our investigators, patients, patient advocacy groups and investors over the course of the last five years. #Biotech #Innovation #hypoparathyroidism https://brnw.ch/21wHRlM

Did you know patients with #hypoparathyroidism (HPT) are 5x more likely to have long-term kidney complications, with 26% of patients already living with chronic kidney disease due to elevated urinary calcium levels? Learn more about our drug candidate designed to treat HPT while normalizing hypercalciuria: https://brnw.ch/21wHR9a #WorldKidneyDay

#JoinOurTeam! We’re seeking a Senior Medical Writer based in the U.S. to join our expanding Medical Affairs team and translate complex science into impactful content, including abstracts, posters, and manuscripts. Learn more and apply here: https://brnw.ch/21wHPDs